Your browser doesn't support javascript.
loading
Identification of a founder BRCA1 mutation in the Moroccan population.
Quiles, F; Teulé, À; Martinussen Tandstad, N; Feliubadaló, L; Tornero, E; Del Valle, J; Menéndez, M; Salinas, M; Wethe Rognlien, V; Velasco, A; Izquierdo, A; Capellá, G; Brunet, J; Lázaro, C.
Affiliation
  • Quiles F; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, ICO-IdIBGi, ICO-IGTP), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Teulé À; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, ICO-IdIBGi, ICO-IGTP), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Martinussen Tandstad N; Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
  • Feliubadaló L; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, ICO-IdIBGi, ICO-IGTP), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Tornero E; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, ICO-IdIBGi, ICO-IGTP), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Del Valle J; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, ICO-IdIBGi, ICO-IGTP), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Menéndez M; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, ICO-IdIBGi, ICO-IGTP), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Salinas M; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, ICO-IdIBGi, ICO-IGTP), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Wethe Rognlien V; Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
  • Velasco A; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, ICO-IdIBGi, ICO-IGTP), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Izquierdo A; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, ICO-IdIBGi, ICO-IGTP), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, ICO-IdIBGi, ICO-IGTP), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, ICO-IdIBGi, ICO-IGTP), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL, ICO-IdIBGi, ICO-IGTP), L'Hospitalet de Llobregat, Barcelona, Spain. clazaro@iconcologia.net.
Clin Genet ; 90(4): 361-5, 2016 10.
Article in En | MEDLINE | ID: mdl-26864382
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Founder Effect / BRCA1 Protein / Mutation Type of study: Diagnostic_studies / Prognostic_studies Limits: Adult / Female / Humans / Middle aged Country/Region as subject: Africa Language: En Journal: Clin Genet Year: 2016 Type: Article Affiliation country: Spain
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Founder Effect / BRCA1 Protein / Mutation Type of study: Diagnostic_studies / Prognostic_studies Limits: Adult / Female / Humans / Middle aged Country/Region as subject: Africa Language: En Journal: Clin Genet Year: 2016 Type: Article Affiliation country: Spain